New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by 2027 Milestone marks progress on AbbVie’s long-term… Read More
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned… Read More
New technology could cut tissue analysis time from weeks to days, advancing research workflows and improving future patient care pathways Vancouver, BC — A new partnership between Providence Health Care… Read More
Download PDF Research suggests AI may help identify more aggressive breast cancers and perform comparably to experts in breast cancer screening MARLBOROUGH, Mass — Data from two groundbreaking studies evaluating… Read More
VANCOUVER, BC — ME Therapeutics Holdings Inc. (“ME Therapeutics”) a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce its… Read More
